Ann: FDA Supports Accelerated Approval Pathway for Heart Failure, page-541

Hi @dolcevita

We've seen before what can happen when shorts over do it and spook stocks and investors. This has been a hunting ground. Many have fallen to these vultures. However, we both know it creates opportunity and GG has seized this in recent months and weeks (the accumulation may not be over). There is some comfort for me knowing that this type of investor, in an area of Florida that has many like minded investors has decided to back SI.

There will be periods whereby the SP will take a breather, after a run, albeit at a much higher price. This is normal, until the next announcement hits (fingers crossed). Timing the lowest entry point, especially in biotech stocks is difficult.

The question for long term investors must always be, at this stage of the company's history and knowing what we know, is the market cap of US$600m cheap or dear to long term valuations?

IMO it's very cheap and if the cards fall our way there is huge upside for those that can hold and believe.